Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors Research Letter


Authors: Zattarin, E.; Presti, D.; Mariani, L.; Sposetti, C.; Leporati, R.; Menichetti, A.; Corti, C.; Benvenuti, C.; Fucà, G.; Lobefaro, R.; Ligorio, F.; Provenzano, L.; Vingiani, A.; Del Vecchio, M.; Griguolo, G.; Sirico, M.; Bernocchi, O.; Marra, A.; Zagami, P.; Agostinetto, E.; Jacobs, F.; Di Mauro, P.; Esposito, A.; Giorgi, C. A.; Lalli, L.; Boldrini, L.; Giacchetti, P. P. B.; Schianca, A. C.; Guarneri, V.; Pedersini, R.; Losurdo, A.; Zambelli, A.; Generali, D.; Criscitiello, C.; Curigliano, G.; Pruneri, G.; de Braud, F.; Dieci, M. V.; Vernieri, C.
Title: Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Abstract: Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting. © 2023, The Author(s).
Keywords: controlled study; human tissue; unclassified drug; overall survival; biological marker; progression free survival; epidermal growth factor receptor 2; cohort analysis; multicenter study; hormonal therapy; estrogen receptor; observational study; protein serine threonine kinase inhibitor; cancer prognosis; advanced breast cancer; human; female; article; cyclin dependent kinase 4 inhibitor; cyclin dependent kinase 6 inhibitor; human epidermal growth factor receptor 2 negative breast cancer
Journal Title: npj Breast Cancer
Volume: 9
ISSN: 2374-4677
Publisher: Nature Publishing Group  
Date Published: 2023-01-01
Start Page: 27
Language: English
DOI: 10.1038/s41523-023-00534-1
PROVIDER: scopus
PMCID: PMC10110597
PUBMED: 37069173
DOI/URL:
Notes: Article -- Export Date: 1 May 2023 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Antonio Marra
    46 Marra